Breadcrumb

Photograph of Charalampos Floudas

Charalampos “Harris” S. Floudas, MD, DMSc, MS

  • Center for Cancer Research
  • National Cancer Institute
Assistant Research Physician
Center for Immuno-Oncology
Head of HNC Therapy, Immunotherapy Section

RESEARCH SUMMARY

Dr. Floudas is a Head and Neck Cancer (HNC) Medical Oncologist. He is clinically active in drug development for HNC, designing and conducting early-phase immunotherapy clinical trials, addressing Squamous Cell Cancer of the Head and Neck (HNSCC/SCCHN), but also rare cancers, such as Nasopharyngeal Cancer and Olfactory Neuroblastoma (esthesioneuroblastoma). His translational research interests include applying artificial intelligence (AI) and machine learning (ML) to multi-modal omics data for clinical predictive modeling and biomarker discovery, and the exploration of LLM applications in Oncology, particularly in patient-clinical trial matching. He is also studying cancer disparities, focusing in equitable access to cancer clinical trials.

Areas of Expertise

Cancer Immunology and Immunotherapy
Medical Oncology
Biomarker Discovery
Clinical Computational Oncology
Artificial Intelligence/Machine Learning

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Publications

Selected Publications

Increasing diversity in clinical trials: Demographic trends at the National Cancer Institute, 2005-2020.

Choradia N, Karzai F, Nipp R, Naqash AR, Gulley JL, Floudas CS
JNCI. 2024.
Full-Text Article
[ Journal Article ]

Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study

Giovanni Maria Iannantuono, Dara Bracken-Clarke, Fatima Karzai, Hyoyoung Choo-Wosoba, James L Gulley, Charalampos S Floudas
The Oncologist. 2024.
Full-Text Article
[ Journal Article ]

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares
HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes G de L, Park W, Garrido-Laguna I.
Journal for ImmunoTherapy of Cancer (JITC) . 2023.
Full-Text Article
[ Journal Article ]

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer

Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, Asaf Maoz, Amin H Nassar, Elio Adib, Khalil Choucair, Joanne Xiu, Yasmine Baca, Biagio Ricciuti, Joao V Alessi, Mark M Awad, Chul Kim, Julia Judd, Luis E Raez, Gilberto Lopes, Jorge J Nieva, Hossein Borghaei, Naoko Takebe, Patrick C Ma, Balazs Halmos, David J Kwiatkowski, Stephen V Liu, Hirva Mamdani
JCO Precision Oncology. 8: 2024.
Full-Text Article
[ Journal Article ]

A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer

Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C.
Clin Colorectal Cancer. Epub ahead of print, 2019. [ Journal Article ]